https://endpts.com/fda-approves-daiichis-new-first-line-aml-drug-quizartinib/
0
0
7/21/23 at 11:07am
Organization
Endpoints News
Author
Katherine Lewin
Patients with a rarer form of acute myeloid leukemia now have a frontline treatment option for the first time, thanks to the FDA's approval of Vanflyta (quizartinib), Daiichi Sankyo announced late Thursday. Vanflyta has been approved for FLT3-ITD-positive AML…
Create an account
or login to join the discussion